BioVendor Group Unveils Latest Innovations in Immunodiagnostics and Molecular Diagnostics
|
By LabMedica International staff writers Posted on 08 Feb 2024 |
|
BioVendor Group (Brno, Czech Republic) is participating in Medlab Middle East 2024 where it is unveiling the latest innovations in immunodiagnostics and molecular diagnostics. Visitors to the BioVendor booth at the show can explore its portfolio and meet experts from BioVendor LM, BioVendor MDx, TestLine, DiaSource, and ViennaLab to discuss how its advancements can benefit their work in the field of laboratory medicine.
BioVendor Group CLIA solution brings a fully automated walk-away platform, which significantly increases the efficiency of the laboratory workflow. It redefines the standards of fluency of diagnostic laboratories and provides reliable results. The KleeYa analyzer is also part of the booth and is being demonstrated to visitors by an application specialist. The KleeYa analyzer is an open platform system that handles tests from various providers and can combine a wide variety of assay designs. KleeYa provides a unique approach to the use of different bead-based chemiluminescence technologies, offering superior assay performance and providing ease of use with cost containment.
At the BioVendor booth, TestLine is presenting its latest innovations in laboratory diagnostics that are shaping the future of diagnostics. Visitors can explore the versatility of its Microblot-Array technology and its impact on the development of laboratory diagnostics worldwide. Microblot–Array is a new generation of unique, immunoblot arrays in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The technology eliminates the limited capacity of traditional BLOT strips and opens the opportunity for high throughput testing. Processing can be performed automatically using open ELISA analyzers. The evaluation is performed by the Microblot–Array Reader and software (SW). Results can be exported in various formats and the system can be connected to LIS.
DiaSource ImmunoAssays is also sharing the same booth as BioVendor Group where it is presenting its latest diagnostic devices, recent innovations, and equipment in the fields of immunodiagnostics and molecular diagnostics. On display are the company’s RIA instruments, IMMUNOBLOT instruments, ELISA instruments, and CLIA instruments. Experts from BioVendor MDx are presenting its expanded fastGEN portfolio with user-friendly kits for the analysis of various genes. The latest addition is the fastGEN TP53 Cancer kit which is intended for the detection of mutations in exons 2-11 as well as in the two non-canonical exons between exons 9 and 10. Visitors to the booth can also learn more about the all-in-one solution fastGEN including bioinformatic analysis software GENOVESA.
.jpg)
Latest Medlab 2024 News
- Anbio Biotechnology Presents Point-Of-Care IVD Solutions
- 77 Elektronika Showcases Latest Developments in Urinalysis
- Sansure Presents Future of Pathogen Identification and Disease Diagnosis
- Spinreact Presents Latest Developments in IVD
- Alifax Demonstrates Automated Solutions to Improve Performance in Laboratory Settings
- YHLO Unveils New iBC 900 Automated Chemistry Analyzer
- Lifotronic Demonstrates Latest Medical Innovations in Disease Diagnostics
- Dymind Introduces New High-End Hematology Analyzer with Innovative Functions
- DIRUI Exhibits Latest Lab Automation Technologies and Devices
- Beckman Coulter Unveils DxC 500 AU Chemistry Analyzer
- Boule Presents Next Generation Hematology and Clinical Chemistry Systems
- bioMérieux Showcases Advanced Generation of VIDAS Immunoassay Solution
- BioPerfectus Highlights Diagnostic Solutions for HPV & Cervical Cancer Screening, STIs and Vector-Borne Diseases
- Mindray Showcases Range of Advanced Total IVD Solutions
- Medlab Middle East 2024 Provides a Peek into the Laboratory of the Future
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Molecular Diagnostics
view channel
New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
Chemotherapy resistance hampers treatment of triple-negative breast cancer (TNBC), particularly in tumors with TP53 mutations. Identifying biomarkers that signal resistance while pointing to actionable... Read more
Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
Pancreatic cancer remains difficult to detect at a curable stage and is associated with poor survival outcomes. In Japan, the five-year relative survival rate is 8.5%, while early-stage disease accounts... Read more
Hematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read more
Immunology
view channel
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Pathology
view channel
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more
